Lumen Bioscience, Inc.

LumenBiologic Drug for Covid-19

SHARE

Covid-19 is widely known as a respiratory disease, but its GI symptoms are well documented. The now-famous ACE2 receptor is abundantly expressed on the cells lining the GI tract, and over half of Covid-19 sufferers show symptoms of GI distress, and up to a quarter show only GI symptoms. GI infection by the virus can have serious long-term effects, and high enteric viral loads are thought to contribute to fatalities from acute respiratory distress syndrome (ARDS) and wet-lung disease. Lumen’s Covid-19 product is designed to block GI infection and rapidly flush the virus from the GI tract, thereby reducing disease symptoms and potentially reducing transmission rates.

Most popular related searches

Covid-19
(SARS-CoV-2)

Mode of action: Neutralizing antibody cocktail

Initiated Summer 2020